Passive Immunotherapy In Patients With SARS CoV-2

Inclusion criteria

Patients with SARS-CoV-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with COVID-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air.

In addition, the patients had to present some risk factor for severe disease:

• Chronic heart failure (NYHA ≥ 2)
• Arterial hypertension under pharmacological treatment
• Chronic lung disease: COPD (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation)
• Chronic renal failure (glomerular filtration rate <60 ml/min/1.73 m², by CKD- ILD)
• Diabetes mellitus requiring pharmacological treatment or obesity grade ≥ I (BMI ≥30 Kg/m2).
• Patients ≥65 years were included, regardless of other risk factors.

Exclusion criteria

• Duration of symptoms >5 days
• Dyspnoea at rest
• Need for supplemental oxygen to maintain O2 saturation >93%
• Solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms
• Patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment
• Decompensated liver cirrhosis
• Participation in another clinical trial
• History of hypersensitivity to haematological derivatives
• Pregnancy or lactation,
• AST/ALT >5 times the upper limit of normal or at baseline in patients with chronic liver disease
• Any condition that in the opinion of the investigator limits participation in the study.
• Patients who had received monoclonal antibodies against SARS-CoV-2